此次Botox Cosmetic的批准是基于3期临床试验的数据，这些数据表明，与安慰剂相比，该疗法能显著改善颈阔肌带的外观，使其成为同类产品中首个扩展到面部以外使用的产品。The United States FDA has approved the fourth indication of Botox Cosmetic under the abbvie umbrella, marking the first time this anti-wrinkle therapy has been expanded beyond the face.
Zhixun Finance APP learned that the US Food and Drug Administration (FDA) recently approved the fourth indication of Botox Cosmetic under AbbVie Inc. (ABBV.US), marking the first time this anti-wrinkle therapy has been expanded beyond the face. This new approval will allow adults to temporarily improve the appearance of moderate to severe vertical bands between the jaw and neck (platysma bands) using Botox Cosmetic.
As the first and only product on the market to receive approval for four cosmetic indications, Botox Cosmetic has previously been used to improve forehead lines, frown lines, and crow's feet. AbbVie acquired Allergan for $63 billion in 2020, further expanding its product line in the medical aesthetics field.
The approval of Botox Cosmetic this time is based on data from phase 3 clinical trials, which demonstrate that compared to a placebo, the therapy can significantly improve the appearance of platysma bands, making it the first product in its category to extend its use beyond the face.
